Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.
Actively Recruiting
Researchers are studying the effects of PIPE-791 in adults aged 40 years and older with Idiopathic Pulmonary Fibrosis IPF, a lung disease characterized by progressive scarring. This Phase 2, randomized, double-blind, placebo-controlled global study aims to evaluate the efficacy, safety, tolerability, and how the body processes PIPE-791 in participants who may or may not be receiving other approved IPF treatments. The study is sponsored by Contineum Therapeutics and will enroll approximately 324 participants. Participants will be assigned to one of three groups two different daily oral doses of PIPE-791 or a placebo. The treatment period lasts 26 weeks. The full study duration extends up to 36 weeks, including screening before treatment and follow-up after treatment ends. Participants receive their assigned tablets daily during the treatment phase. Throughout the study, participants will undergo lung function tests such as forced vital capacity FVC, high-resolution CT scans to assess lung fibrosis, and safety monitoring for any side effects or adverse events. Researchers will track changes in lung function and overall health from the start of treatment to week 26, with additional safety follow-up until week 30. The study involves regular visits for assessments, and participant involvement may last up to 36 weeks in total.